⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 2, 2025Open Access

Figure S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies

Michael Wichroski Si-Qi Liu Lauren M. Zasadil Joseph L. Benci Patrick C. Gedeon Kendall J. Condon Suhasini Joshi Shana Posy Patrick Carlson Alison Maier Jiao Shen Rakeeb Kureshi Yuka Amako Tai Wang Ryan L. Powles Yanyun Li Tho Lai Igor Katsyv Hongchen Qiu Huilin Qi Jessica Wong Dandan Zhao Dana Banas Joelle M. Onorato Gregory Locke Xueer Chen Wen‐Chi Chou Erica Cook Abigail E. Witt Christopher M. Barbieri Hong Zhang Jonathan B. Olsen Alba Font‐Tello Eugene Drokhlyansky Denise C. Grünenfelder Louis Chupak Tyler A. Longmire Jon C. Jones Travis J. Hollmann David Kugler John N. Feder Raphael Bueno John C. Wain Pallavur Sivakumar Yu Liu Stephanie K. Dougan Cloud P. Paweletz David A. Barbie Emma Lees

View Full Paper

Ask AI

Bookmark

Share

Key Points

BMS-986408 effectively enhances the immune response by inhibiting DGKα and DGKζ, leading to improved CAR T-cell activity.
Key evidence shows that BMS-986408 boosts PD-1 checkpoint therapy performance in vitro via a novel mechanism.
Observational analysis details the nuanced action of BMS-986408 on immune modulation and tumor response.
This work supports the potential of combining dual inhibitors with immunotherapy to achieve better cancer treatment results.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Observational analysis illustrates BMS-986408's mechanism of action, suggesting synergy with PD-1 checkpoint and CAR T-cell therapies.

Abstract

Fig. S2. Additional BMS-986408 mechanism of action data.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wichroski et al. (2025) studied this question.

synapsesocial.com/papers/68c182609b7b07f3a060f58f https://doi.org/10.1158/2326-6066.30029428

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025
2Figure S7 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025
3Figure S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025
4Figure S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025
5Figure S3 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025

More related papers

Data from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025
Design, Synthesis, and T Cell Checkpoint Combination Potential Of First-In-Class DGKα/ζ Inhibitor BMS-9864082025
Discovery of INCB191358: A Potent and Selective DGKα/ζ Dual Inhibitor2026